Rodney J Y

High-extraction protease inhibitors (e.g., for HIV and COVID-19) typically require ritonavir to enhance bioavailability by overcoming first-pass metabolism. However, in the long-acting subcutaneous injectable dosage form TLC-ART 101, lopinavir persisted in plasma for 57 days, while ritonavir was detectable for only 3–7 days.

Introduction The two most commonly used nucleos(t)ide reverse transcriptase inhibitors (NRTIs), tenofovir (TFV) and emtricitabine (FTC), in antiretroviral (ARV) therapy (ART) for HIV-infection in humans are also the ones, but only in combination with one another, approved for daily use as pre-exposure prophylaxis (PrEP) of HIV prevention strategy. In HIV-infection in humans and SIV-infection of rhesus macaques (RMs), lymphoid tissues are a major site of viral production and storage (1).